tbuckley/cabot-search huggingface dataset:
Some studies of the excretion of diazotizable material after feeding 2-acetylaminofluorene to rats.
Authors: Harold P. Morris, Benton B. Westfall
Journal: Cancer Research (1950)

2-Acetylaminofluorene (AAF), in solution in coconut oil, was fed by stomach tube to rats, under different conditions. The acid-hydrolyzable, diazotizable material excreted in the urine was estimated colorimetrically as 2-aminofluorene but calculated as AAF.

There was a rapid rise in urinary concentration following a final dose which reached a peak between 4 and 6 hours. There was a slower decline in concentration during the next 14 hours until the base level was reached at approximately 20 hours. Only a trace of diazotizable material was recovered from the urine following the ingestion of 0.25 mg/week/100 gm rat, divided into three equal feedings. Increasing the dose to 1.0, to 4.0, and to 16.0 mg/week resulted in a direct increase in urinary excretion which reached a maximum of 45 per cent on the highest dose. When the 16.0-mg. dose was administered in six instead of three weekly feedings, the amount found in the urine amounted to only 28 per cent.

Rats uniformly excrete in their urine approximately a third of the AAF ingested as diazotizable compound weekly for several weeks, and approximately one-third of a final feeding was recovered in the urine during the subsequent 8.5 days. None was detected thereafter.
Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors
Authors: Wataru Shibata, Hiroshi Ariyama, Christoph Benedikt Westphalen, Daniel L. Worthley, Sureshkumar Muthupalani, Samuel Asfaha, Zinaida Dubeykovskaya, Michael Quante, James G. Fox, Timothy C. Wang
Journal: BMJ (2012)

Objective  Stromal cell-derived factor-1 (SDF-1/CXCL12), the main ligand for CXCR4, is overexpressed in human cancer. This study addressed the precise contribution of SDF-1 to gastric carcinogenesis.  Design  SDF-1 transgenic mice were created and a  Helicobacter -induced gastric cancer model was used in combination with H/K-ATPase-IL-1β mice. Gastric tissue was analysed by histopathology and cells isolated from the stomach were analysed by molecular biological methods.  Results  Analysis of the H/K-ATPase/SDF-1 transgenic (SDF-Tg) mice showed that SDF-1 overexpression results in significant gastric epithelial hyperproliferation, mucous neck cell hyperplasia and spontaneous gastric dysplasia (wild-type mice 0/15 (0%) vs SDF-Tg mice 4/14 (28.6%), p=0.042, Fisher exact test) but has minimal effects on inflammation. SDF-Tg mice also showed a dramatic expansion of α-smooth muscle actin-positive myofibroblasts and CXCR4-expressing gastric epithelial cells in the progenitor zone, both of which preceded the development of significant gastritis or dysplasia. Gremlin 1-expressing mesenchymal stem cells, the putative precursors of myofibroblasts, were also increased within the dysplastic stomachs of SDF-Tg mice and showed chemotaxis in response to SDF-1 stimulation. SDF-1 overexpression alone resulted in minimal recruitment of haematopoietic cells to the gastric mucosa, although macrophages were increased late in the disease. When SDF-Tg mice were crossed with H/K-ATPase-IL-1β mice or infected with  Helicobacter felis , however, there were dramatic synergistic effects on recruitment of bone marrow-derived cells and progression to preneoplasia.  Conclusion  Activation of the SDF-1/CXCR4 axis can contribute to early stages of carcinogenesis primarily through recruitment of stromal cells and modulation of the progenitor niche.
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
Authors: A J Lees
Journal: BMJ (1995)

<h3>Abstract</h3> <b>Objective:</b> To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson9s disease <b>Design:</b>Open, long term, prospective randomised trial. <b>Setting:</b>93 hospitals throughout United Kingdom <b>Subjects:</b>520 patients with early Parkinson9s disease who were not receiving dopaminergic treatment. <b>Interventions:</b>Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2). <b>Main outcome measures</b> Assessments of serial disability, frequency and severity of adverse events, and deaths from all causes. <b>Results:</b>After average of 5.6 years9 follow up, mortality ratio in arm 2 compared with arm 1 was 1.57 (95% confidence interval 1.09 to 2.30), and difference in survival between the two arms was significant (log rank test, P=0.015). Hazard ratio adjusted for age and sex was 1.49 (1.02 to 2.16), and after adjustment for other baseline factors it increased to 1.57 (1.07 to 2.31). Patients in arm 1 had slightly worse disability scores than those in arm 2, but differences were not significant. Functionally disabling peak dose dyskinesias and on/off fluctuations were more frequent in arm 2 than arm 1. During the trial the dose of levodopa required to produce optimum motor control steadily increased in arm 1 (median daily dose 375 mg at 1 year and 625 mg at 4 years), but median dose in arm 2 did not change (375 mg). <b>Conclusion:</b>Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson9s disease. Moreover, mortality was significantly higher with combination treatment, casting doubts on its chronic use in Parkinson9s disease.
Abstract 4302: The development study of hypoxia responsive chemiluminescent probe for tumor hypoxia imaging
Authors: Kensuke Okuda, Toru Ban, Tasuku Hirayama, Hideko Nagasawa
Journal: Cancer Research (2014)

Abstract Introduction: The tumor microenvironment is recognized as a major factor that influences not only the response to conventional anticancer therapies but also the potential for malignant progression and metastasis. Therefore, it is considered that tumor hypoxia imaging is critical for cancer diagnosis and therapy. As optical modalities offer the advantages of non-invasive, easy-to-handle, and cost-effective imaging, much effort has been done to develop synthetic fluorescent imaging probes for tumor hypoxia. In particular, we focus our attention on chemiluminescence imaging which can avoid interference from tissue autofluorescence and scattering light. We therefore show the development of hypoxia responsive chemiluminescent probe, which has the advantage of lower detection limits and improved signal-to-noise ratio compared to existing fluorescent probes. Results and discussion: In our molecular design, luminescence is derived from 1,2-dioxetane cleavage triggered by hypoxia-selective enzymatic reduction of electron-deficient aromatics. At the start, nitrobenzyl moiety was chosen as a bioreductively cleavable protective group linked to 1,2-dioxetane moiety through phenyl ether linker to construct synthetic probe NB-Adm. The compound was synthesized from 2-adamantanone in 19% (overall yield, 6 steps). Then NB-Adm was attempted to be reduced by nitroreductase, however, no luminescence was observed. HPLC analysis of the reaction mixture indicated that our expected reduction did not occur, probably because bulky adamantane moiety prevented the enzymatic reaction owing to steric hindrance. Therefore, a self-immolative linker was employed to keep away 1,2-dioxetane moiety from enzyme recognition moiety. In this time, quinone moiety was chosen as a protective group which was expected to be better substrate than nitrophenyl one in terms of their redox potential. This newly designed compound, TMQ-Adm was synthesized from 2-adamantanone in 16% (overall yield, 6 steps). By the use of TMQ-Adm, we successfully observed luminescent emission from the reaction with nitroreductase. This implied that our bioredctively activatable probe can be applicable for chemiluminescence imaging for tumor hypoxia. Now we are investigating to develop chemiluminescent probe to realize in vivo imaging of tumor hypoxia by improving luminescent quantum yield under physiological condition. Citation Format: Kensuke Okuda, Toru Ban, Tasuku Hirayama, Hideko Nagasawa. The development study of hypoxia responsive chemiluminescent probe for tumor hypoxia imaging. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4302. doi:10.1158/1538-7445.AM2014-4302
Twin Figures (Ere Ibeji)
Authors: M. Therese Southgate
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Guidelines for the public health management of typhoid and paratyphoid in England
Authors: S. Balasegaram, A.L. Potter, D. Grynszpan, S. Barlow, R.H. Behrens, L. Lighton, L. Booth, L. Inamdar, K. Neal, K. Nye, J. Lawrence, J. Jones, I. Gray, D. Tolley, C. Lane, B. Adak, A. Cummins, S. Addiman
Journal: Journal of Infection (2012)
Abstract 1857: Prognostic biomarker for SNP (-617C-A) in ARE-like loci of the <i>NRF2</i> gene in lung adenocarcinoma
Authors: Yasuko Okano, Yasushi Ichikawa, Yohei Miyagi, Keiichi Kondo, Yutaka Natsumeda
Journal: Cancer Research (2014)

Abstract Purpose: We here report that SNP (c.-617C&amp;gt;A; rs6721961) in the ARE-like region of NRF2 gene is associated with Japanese non-smoking female patients with adenocarcinoma and their overall survival. Experimental Design: We prepared genomic DNA samples from 387 Japanese patients with primary lung cancer and detected a SNP (-617C&amp;gt;A) in NRF2 gene by the rapid genetic testing method we developed in this study. We analyzed the association between the SNP in the NRF2 gene and overall survival. Results:Patients harboring wild-type -617C/C, -617C/A, and -617A/A alleles numbered 216 (55.8%), 147 (38.0%), and 24 (6.2%), respectively. Multivariate logistic regression models revealed that SNP homozygote (-617A/A) was significantly related to gender. Its frequency was four-fold higher in female patients than in males (10.8% female vs 2.7% male) and was associated with female non-smokers with adenocarcinoma. Interestingly, lung cancer patients carrying the SNP homozygous alleles (-617A/A) and the 309T (WT) allele in the MDM2 gene exhibited remarkable survival over 1,700 days after surgical operation (log-rank p=0.021). Conclusion: SNP homozygous (-617 A/A) alleles in the NRF2 gene are associated with female non-smokers with adenocarcinoma and regarded as a prognostic biomarker for assessing overall survival of patients with lung adenocarcinoma. Citation Format: Yasuko Okano, Yasushi Ichikawa, Yohei Miyagi, Keiichi Kondo, Yutaka Natsumeda. Prognostic biomarker for SNP (-617C-A) in ARE-like loci of the NRF2 gene in lung adenocarcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1857. doi:10.1158/1538-7445.AM2014-1857
Influence of hospital and clinician workload on survival from colorectal cancer: cohort study
Authors: Moore M, Carrol D, Jenkinson C, Reynolds Djm, Gavaghan Dj, Perez Ma
Journal: BMJ (1999)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Influence of hospital and clinician workload on survival from colorectal cancer: cohort study Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Strontium-89 and Strontium-90 Levels in Breast Milk and in Mineral Supplement Preparations
Authors: A A JARVIS, J R BROWN, B TIEFENBACH
Journal: JAMA (1963)

Strontium-90, strontium-89 and S.U. values were determined in human milk before and after the resumption of atmospheric nuclear testings in 1961, and the levels were compared to cows' milk values reported during the same time. S.U.(90) levels in human milk were approximately one-fifth of those found in cows' milk. Assuming an average dietary intake of 11-13 S.U.(90) during the period tested, the mean strontium/calcium ratio of 1.78 found in human milk represents an Observed Ratio milk-diet of approximately 0.14-0.16. Although strontium-89 was present in cows' milk already in September 1961, it did not appear in human milk until November 1961. It seems, therefore, that there was a two-month lag period between the appearance of fresh fallout in cows' milk and human milk. Calcium-supplement mineral preparations used by pregnant and lactating women were tested to find their strontium-89, strontium-90 and S.U. levels, because strontium isotopes, if present in these products, will be transferred to the fetus and to breast-fed infants. The compounds tested had S.U.(90) levels of 0.13-2.62; in none of the preparations was Sr(89) present.
Prey of Pain
Authors: Bonnie Raingruber
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of parametric response mapping for monitoring COPD subtypes
Authors: Craig Galban, Jennifer Boes, Bennjamin Hoff, Maria Bule, Timothy Johnson, Ella Kazerooni, Fernando Martinez, Meilan Han, Brian Ross
Journal: European Respiratory Journal (2014)

Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction that may be emphysematous and non-emphysematous in origin, ultimately complicating diagnosis. We evaluated and established guidelines for the parametric response mapping (PRM), a technique that spatially segments parenchyma as normal (PRMNormal), emphysematous (PRMEmph) and non-emphysematous tissue (PRMfSAD), to monitor longitudinal changes in COPD subtypes in subjects accrued for the SPIROMICS study. PRM was performed on inspiratory/expiratory CT scans acquired from subjects in intervals of 30 day (n=13) and one year (n=76; overall GOLD). Six percent variation in the 30-day data was observed for PRMNormal and PRMfSAD, and less than 2% for PRMEmph. Using cutoffs determined from 30-day data, PRM analysis of serial one-year data showed 11 of 76 subjects had significant changes in PRMfSAD with 7 showing a drop. PRM images at baseline and 1-year follow-up are provided from a representative subject that produced a significant drop in PRMfSAD (yellow voxels), which also had improvement in FEV1 from 1.36L to 1.94L. Mathematical model simulations showed agreement with PRM analysis of CT data, suggesting fSAD (i.e. non-emphysematous tissue) may serve as a transitional phase from normal parenchyma to emphysema. PRM of COPD patients provides an opportunity to more fully characterize patients based on disease subtyping.

![Figure][1]  [1]: pending:yes
End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation
Authors: Jucylea M Cwajg, Eduardo Cwajg, Sherif F Nagueh, Zuo-Xiang He, Usman Qureshi, Leopoldo I Olmos, Miguel A Quinones, Mario S Verani, William L Winters, William A Zoghbi
Journal: Journal of the American College of Cardiology (2000)
SO-CALLED "INFARCTION TYPE" ELECTROCARDIOGRAPHIC CHANGES FOLLOWING PAROXYSMAL TACHYCARDIA
Authors: Sylvan D. Solarz
Journal: Annals of Internal Medicine (1947)

Case Reports1 September 1947SO-CALLED "INFARCTION TYPE" ELECTROCARDIOGRAPHIC CHANGES FOLLOWING PAROXYSMAL TACHYCARDIASYLVAN D. SOLARZSYLVAN D. SOLARZSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-27-3-447 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe problem of the early diagnosis of myocardial infarction in the age group of those serving in the armed forces has been difficult. In the early days of the emergency the diagnosis was not made promptly because of the lack of experience with this disease in relatively young men. The easy availability of electrocardiograms has made the diagnosis more certain in many instances, but at the other extreme there has been the tendency to err on the conservative side and to read too much into the tracings. Then too, relatively rare conditions have been called infarction without careful analysis with...Bibliography1. GEIGER AJ: Electrocardiogram simulating those of coronary thrombosis after cessation of paroxysmal tachycardia, Am. Heart Jr., 1943, xxvi, 556. Google Scholar2. ZIMMERMAN SL: Transient T-wave inversion following paroxysmal tachycardia, Jr. Lab. and Clin. Med., 1944, xxix, 598. Google Scholar3. EISAMAN JL: Electrocardiograms simulating posterior myocardial infarction after cessation of paroxysmal tachycardia, Am. Heart Jr., 1945, xxx, 401. CrossrefGoogle Scholar4. WARD LS: Abnormal electrocardiogram following recovery from paroxysmal tachycardia, Am. Heart Jr., 1946, xxxi, 645. CrossrefGoogle Scholar5. CAMPBELL M: Inversion of T-waves after long paroxysms of tachycardia, Brit. Heart Jr., 1942, iv, 49. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication November 1, 1946.†From the Cardiovascular Section, Wakeman General Hospital, Camp Atterbury, Indiana. Present address: Michael Reese Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Rhythmusstörungen des Herzens (einschließlich der intramuralen Leitungsstörungen und des Alternans)Paroxysmal ventricular tachycardia of prolonged duration 1 September 1947Volume 27, Issue 3Page: 447-454KeywordsAge groupsArmed forcesCyclic adenosine monophosphateElectrocardiographyInfarctionMyocardial infarctionTachycardia ePublished: 1 December 2008 Issue Published: 1 September 1947 PDF downloadLoading ...
LIPID STUDIES IN PATIENTS WITH ADVANCED DIABETIC ATHEROSCLEROSIS
Authors: L T DeWIND, D MICHAELS, L W KINSELL
Journal: Annals of Internal Medicine (1952)

In recent years, interest in the problem of human atherosclerosis has been great. Since the early observations on atheromatous lesions in cholesterol-fed rabbits,1, 2 there have been many studies on the possible rôle of elevated blood cholesterol in the genesis of atherosclerosis. The work of Gofman and his co-workers3 has been of interest in this connection through their demonstration of a technic for measuring cholesterol-bearing lipoproteins in serum. The group of molecules known as the Sf10-20 group, according to Svedberg's designation of flotation densities, has been reported to be elevated in individuals with coronary artery disease and is thought by
Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions
Authors: P.A. Ascierto, G. Palmieri, E. Celentano, R. Parasole, C. Caracò, A. Daponte, M.G. Chiofalo, M.T. Melucci, N. Mozzillo, R.A. Satriano, G. Castello
Journal: British Journal of Dermatology (2000)

To evaluate the role of epiluminescence microscopy (ELM) in the differential diagnosis of cutaneous pigmented lesions, and to improve the early diagnosis of cutaneous malignant melanoma (CMM), 15,719 pigmented lesions from 8782 consecutive patients were evaluated using ELM with a hand-held video microscope imaging system (MS 500B Micro-Scopeman, Moritex). Comparison between risk levels as inferred from ELM screening and histology was performed on 2731 surgically excised lesions. ELM sensitivity, specificity, positive and negative predictive values, as well as agreement with histological results for the different subgroups of lesions, were determined. Overall agreement was 87·3% (ranging from 85·1% to 92·2% for melanocytic and non-melanocytic lesions, respectively); sensitivity and specificity were high (values ranging from 87·3% to 96·3% among different subsets of ELM-analysed lesions) and statistically significant (P < 0·0001). ELM screening identified 165 new cases of CMM with a high proportion of lesions (115; 70%) in an early phase of tumour growth (Breslow thickness ≤ 1·5 mm). Thus, ELM is helpful to the clinician in deciding which pigmented lesions need surgical excision, as well as in diagnosing early CMM lesions.
How to survive in the private practice of psychiatry
Authors: S S Sharfstein, A Beigel
Journal: American Journal of Psychiatry (1988)

The private practice of psychiatry is being transformed by the new economics of medical care. Patients are paying more out-of-pocket for necessary care (demand-side cost sharing), and health care providers are being asked to assume part of the risk of treatment through prospective payment (supply-side cost sharing). Specific survival strategies for psychiatrists in private practice include development of a balanced practice, expansion of referral networks, participation in alternative delivery systems such as health maintenance organizations and preferred provider organizations, active involvement in utilization and claims review, participation in outcome studies, and expansion of patient care advocacy and community involvement.
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)
Authors: Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth
Journal: Blood (2002)